Fresenius SE is partnering with China’s WuXi Biologics to develop biosimilar drug candidates, with the potential for some products to reach the market in the next decade. The agreement aims to substantially enlarge Fresenius’s existing biosimilars portfolio through development work on multiple candidates.
Bloomberg frames the deal as a way to expand Fresenius’s biosimilar holdings, suggesting the partnership could more than double the company’s current portfolio. PR Newswire adds more specific terms and scope, describing an exclusive development arrangement that grants option rights tied to a large number of potential first-to-market biosimilars, and it links the opportunity to originator sales figures. Investing.com also reports on the formation of the biosimilars deal, though its provided summary contains no additional detail.
Across the coverage, the main shared point is that the companies are entering a biosimilars development partnership intended to grow Fresenius’s pipeline over the coming decade, with differences mainly in the level of deal specifics and portfolio scale emphasized.
